Summary: INKmune is an NK-targeting immuno-oncology drug allowing treatment in a wide range of NK-related cancers; INKmune’s production...

In my mind's eye, these stairs keep on going into 2023 and the years after. INTRODUCTION The previous five blogs have laid out the...

My views on possible partnership/buyout and valuation of INMB will be set out below. The highlights are the following. - I consider a...

The immuno-oncology platform INKmune of INmune Bio may be a better, easier to produce and cheaper product candidate than others.

INTRODUCTION As an immunotherapy drug candidate, INKmune seems by far the most commercially sustainable, undervalued that I am aware of....

Drug XPro of INmune Bio has limitless potential in neurodegenerative diseases such as Alzheimers, ALS, MS, Huntington's, Parkinson's, ...

Introduction I believe INmune Bio, a company with a market cap of just 200 million dollars at the time of writing, will end up being...